Citi Pharma Ltd. has released its Annual Report for the year ended June 30, 2026, detailing its financial performance and strategic outlook amidst a challenging operating environment.
- Revenue increased by 6.5% to PKR 14,004.6M, driven by local sales and exports.
- Gross profit rose by 21.4% to PKR 2,449.6M, with a gross margin improvement from 15.3% to 17.5%.
- Operating profit grew by 20.0% to PKR 1,925.4M despite rising administrative and marketing expenses.
- Profit after tax (PAT) decreased by 12.3% to PKR 782.6M, resulting in an EPS of PKR 3.43 compared to PKR 3.90 in the previous year.
- The company did not recommend any dividend for the year, citing cash generation and capital expenditure needs.
- The report reflects a focus on operational efficiency and cost management amidst inflationary pressures and regulatory challenges.
- The audit status is confirmed as complete with the report being audited by Aslam Malik & Co.